Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Third Wave Japan was the Japanese subsidiary of Third Wave Technologies, a molecular diagnostics company specializing in high-sensitivity nucleic acid detection. The company is best known for its proprietary Invader assay technology, an isothermal method used for detecting genetic variations, including single nucleotide polymorphisms (SNPs) and infectious agents. In Japan, the company focused on commercializing diagnostic kits for human papillomavirus (HPV) and pharmacogenomic markers such as UGT1A1 for irinotecan toxicity screening. Following the acquisition of the parent company by Hologic in 2008, Third Wave Japan's operations and product portfolio were integrated into Hologic's diagnostic division. The technology remains a cornerstone of molecular testing workflows in clinical laboratories across Japan for personalized medicine and oncology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Third Wave Japan.